Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
The University of Texas MD Anderson Cancer Center · Cornell University · +2 more institutions
Abstract
Purpose No standard treatment exists for patients with cholangiocarcinoma for whom first-line gemcitabine-based therapy fails. Fibroblast growth factor receptor 2 ( FGFR2) fusions/translocations are present in 13% to 17% of intrahepatic cholangiocarcinomas. BGJ398, an orally bioavailable, selective pan-FGFR kinase inhibitor, has shown preliminary clinical activity against tumors with FGFR alterations. Methods A multicenter, open-label, phase II study ( ClinicalTrials.gov identifier: NCT02150967) evaluated BGJ398 antitumor activity in patients age ≥ 18 years with advanced or metastatic cholangiocarcinoma containing FGFR2 fusions or other FGFR alterations whose disease had progressed while receiving prior…
Citation impact
- FWCI
- 24.33
- Percentile
- 100%
- References
- 26
Authors
29- MJMilind JavleCorresponding
The University of Texas MD Anderson Cancer Center, Cornell University, Heidelberg University, University Hospital Heidelberg
- MAMaeve A. Lowery
The University of Texas MD Anderson Cancer Center, Cornell University, Heidelberg University, University Hospital Heidelberg
- RTRachna T. Shroff
The University of Texas MD Anderson Cancer Center, Cornell University, Heidelberg University, University Hospital Heidelberg
- KHKarl Heinz Weiss
The University of Texas MD Anderson Cancer Center, Cornell University, Heidelberg University, University Hospital Heidelberg
- CSChristoph Springfeld
The University of Texas MD Anderson Cancer Center, Cornell University, Heidelberg University, University Hospital Heidelberg
Topics & keywords
- Medicine
- Internal medicine
- Adverse effect
- Hyperphosphatemia
- Hypophosphatemia
- Gastroenterology
- Common Terminology Criteria for Adverse Events
- Clinical endpoint
- Good health and well-being